Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes

Chuang, Linus; Lotzová, Eva; Cook, Kimberly; Cristoforoni, Paolo; Morris, Mark R.; Wharton, J. Taylor

doi:10.1016/0020-7292(94)90216-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune cells depend on the microtubule cytoskeleton for structural reorganization during mitosis as well as during leukocyte polarization and migration (178), phagocytosis (179), and for the release of cytolytic granules (180). Paclitaxel and docetaxel have been shown to inhibit T‐cell and NK cell antitumor function in vitro , although with immunosuppression mainly associated with interference in IL‐2‐mediated activation rather than chemical toxicity (181, 182). Furthermore, paclitaxel has been shown to increase the secretion of monocyte chemoattractant protein 1 (MCP1) by tumor cells (183), presumably leading to the recruitment of MDSCs, which contribute to the formation of an immunosuppressive tumor stroma (184).…”

Section: Combining Anti‐microtubules With Cq and Hcqmentioning

confidence: 99%

Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity

Townsend

Hughson

Schlie

et al. 2012

Immunological Reviews

View full text Add to dashboard Cite

Tumors and the immune system are intertwined in a competition where tilting the fine balance between tumor-specific immunity and tolerance can ultimately decide the fate of the host. Defensive and suppressive immunological responses to cancer are exquisitely sensitive to metabolic features of rapidly growing tumors, such as hypoxia, low nutrient availability, and aberrant growth factor signaling. As a result, clinical therapies impacting these properties change the in situ antitumor immune response by virtue of disrupting the tumor environment. To compensate for disruptions in cellular metabolism, cells activate autophagy to promote survival. On the basis of this notion, strategies designed to block autophagy in tumor cells are currently being tested in several human clinical trials. However, therapies that impair tumor metabolism must also take into account their effect on lymphocytes activated in the immune response to cancer. Given that a strong antitumor immune response is a positive prognostic factor in overall patient survival, identifying ways to block essential processes in tumor cells and suppressive immune cells while promoting those that are important for a robust immune response are of critical importance. Herein, we review the effects of anti-cancer agents that impact metabolism administered concurrently with autophagy inhibitors on immune cells and consider the implications for patient response to therapy.

show abstract

Section: Combining Anti‐microtubules With Cq and Hcqmentioning

confidence: 99%

Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity

Townsend

Hughson

Schlie

et al. 2012

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…There are numerous publications on this subject. Interested readers should consult some of the recent ones (Chuang et al 1993;Runowicz et al 1993;Markman 1993;Lopes 1993 Five plants, which have a long history of effective use in herbal medicine and in tonic food preparations, will be discussed here.…”

Section: Taxus Species and Taxolmentioning

confidence: 99%

Phytochemicals and Antioxidants

Lin¹

1994

Functional Foods

View full text Add to dashboard Cite

Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes

Cited by 2 publications

References 0 publications

Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity

Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity

Phytochemicals and Antioxidants

Contact Info

Product

Resources

About